Approximately 66% of malignant melanomas have BRAF (B-RAF proto-oncogene) mutations, which lead to an increase in constitutive BRAF kinase activity and the MEK-ERK1/2 pathway and are necessary for proliferation, invasion and survival in melanoma cells (127). This evidence concerns the gene MAP2K7 and melanoma.